Previous 10 | Next 10 |
Cantor Fitzgerald analyst Pete Stavropoulos assumed coverage of Orchard Therapeutics (NASDAQ:ORTX) with an Overweight rating with a price target (PT) of $9, down from $12. Shares up 10% premarket $1.19. PT of $9 implies a premium of ~656.3% to the last close. Orchard is de...
ShiftPixy (NASDAQ:PIXY) +53%. MingZhu Logistics Holdings (NASDAQ:YGMZ) +44% on share purchase agreement to acquire CheYi Network. Pop Culture Group (NASDAQ:CPOP) +17%. Can-Fite BioPharma (NYSE:CANF) +17% to file for patents after new findings for liver cancer therapy. Orch...
The Nasdaq Biotechnology Index will have a new look on December 20, before the market opens when 129 securities will be added and 21 securities will be deleted as part of the annual reconstitution. Notable additions to the index: Viatris (NASDAQ:VTRS), NovoCure (NASDAQ:NVCR), Anavex Life Scie...
Dicerna Pharmaceuticals DRNA +78% Novo Nordisk agrees to acquire Dicerna for more than $3 billion Cardiff Oncology (NASDAQ:CRDF) +23% announces $15M equity investment from Pfizer through its Pfizer breakthrough growth initiative Cloopen Group Holding RAAS +19% on Q3 result...
100 percent overall survival with median follow-up of two years post-treatment with HSC gene therapy Preliminary findings show promising metabolic and early clinical outcomes Results warrant further evaluation in global registrational study expected to be initiated in 20...
BOSTON and LONDON, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that members of the management team will present and be available for one-on-one meetings at the following virtual investor conferences: Barclays G...
Orchard Therapeutics (NASDAQ:ORTX): Q3 GAAP EPS of -$0.29 misses by $0.04. Revenue of $1.19M (-40.5% Y/Y) misses by $3.61M. Press Release For further details see: Orchard Therapeutics EPS misses by $0.04, misses on revenue
Updates from OTL-201 Clinical Proof-of-Concept Study in MPS-IIIA and OTL-204 Preclinical Study for GRN-FTD at ESGCT Showcase Potential for HSC Gene Therapy in Multiple Neurodegenerative Disorders Launch Activities for Libmeldy® Across Key European Countries, including Reimb...
BOSTON and LONDON, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced the acceptance of nine abstracts at the upcoming European Society of Gene & Cell Therapy Congress (ESGCT) taking place virtually from October 19-22. ...
The following slide deck was published by Orchard Therapeutics plc in conjunction with this event. For further details see: Orchard Therapeutics (ORTX) Investor Prentation - Slideshow
News, Short Squeeze, Breakout and More Instantly...
Orchard Therapeutics plc Company Name:
ORTX Stock Symbol:
NASDAQ Market:
Orchard Therapeutics plc Website:
TOKYO, LONDON and BOSTON, May 03, 2024 (GLOBE NEWSWIRE) -- Orchard Therapeutics, recently acquired by Kyowa Kirin with the goal of accelerating the delivery of new gene therapies to patients around the globe, today announced that Bobby Gaspar, M.D., Ph.D., co-founder and chief executive officer, ...
Crescent Energy Company Class A (CRGY) is expected to report $0.21 for Q4 2023 ThredUp Inc. (TDUP) is expected to report $-0.13 for Q4 2023 Wright Investors` Service Holdings Inc (IWSH) is expected to report for Q4 2023 Bridgford Foods Corporation (BRID) is expected to report for Q1 2...
Gene therapy being developed as a one-time treatment to address the underlying cause of the disease by inserting a functional copy of the human IDUA gene into a patient’s own hematopoietic stem cells HURCULES study to enroll 40 patients at clinical sites across the U.S....